<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01301885</url>
  </required_header>
  <id_info>
    <org_study_id>ENDOMET-231/2004</org_study_id>
    <nct_id>NCT01301885</nct_id>
  </id_info>
  <brief_title>ENDOMET - Novel Diagnostic Tools and Treatments for Endometriosis</brief_title>
  <acronym>ENDOMET</acronym>
  <official_title>Novel Diagnostic Tools for Endometriosis and Their Exploitation for Prognosis and Prevention of Complications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Finnish Funding Agency for Technology and Innovation (TEKES)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VTT Technical Research Centre of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hormos Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PerkinElmer, Wallac Oy</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biotop Oy</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmatest Services Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Drug Discovery Graduate School, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The National Graduate School of Clinical Investigation, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometriosis is a chronic disease characterized by the presence of functional endometrial&#xD;
      glands and stroma in ectopic locations outside the uterine cavity. The ectopic endometrial&#xD;
      tissue responds to estradiol and other hormones similarly to the normal endometrium.&#xD;
      Endometriosis is one of the most common benign gynecological conditions, as many as 5-10% of&#xD;
      women in the reproductive age may be affected. In addition to pain which may be severe,&#xD;
      subfertility is one of the typical problems associated with endometriosis and may be present&#xD;
      in up to 40% of those affected. There is lack of a clear correlation between severity of pain&#xD;
      and degree of compromised fertility. Different modes of treatment exist. Hormonal treatments&#xD;
      are based on the suppression of estrogenic action on endometriosis as well as the&#xD;
      endometrium. Unfortunately, discontinuation of the hormonal treatment typically results in a&#xD;
      rapid recurrence of the disease. Surgery may alleviate the symptom for different lengths of&#xD;
      time, however, curative treatment frequently involves hysterectomy with bilateral&#xD;
      oophorectomy. In order to escape this radical treatment, new targeted therapy in the form of&#xD;
      novel pharmacological agents would be of crucial importance. Presently, endometriosis can be&#xD;
      reliably diagnosed only by laparoscopy. Since this is an invasive surgical procedure, new&#xD;
      diagnostic tools would be warmly welcomed. Furthermore, as the progression of the disease is&#xD;
      presently impossible to predict, new markers for the &quot;malignancy&quot; of each case are&#xD;
      desperately needed.&#xD;
&#xD;
      The aim of the investigators research is to identify expression of endometriosis specific&#xD;
      RNAs/proteins. Evaluation of expression profiles in samples of endometriosis and endometrium&#xD;
      of patients with careful clinical and surgical classification of endometriosis as well as&#xD;
      healthy control women should initially enable to identify novel targets for new therapies and&#xD;
      biomarkers. Particularly the different pain symptoms will be recorded annually and evaluated&#xD;
      comprehensively. Furthermore, combined with an adequate 10-year follow up (based on a&#xD;
      questionnaire, including fertility, received treatments and different pain symptoms; NRS),&#xD;
      the study should enable for example to identify markers for endometriosis associated&#xD;
      infertility as well as cases where the disease progresses very rapidly or reoccurs. Different&#xD;
      forms of effective treatment may thereafter be designed following the identification of such&#xD;
      factors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Intra-tissue steroid profiling indicates differential progesterone and testosterone metabolism in the endometrium and endometriosis lesions.</measure>
    <time_frame>During the surgical sample collection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels.</measure>
    <time_frame>During the surgical sample collection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts.</measure>
    <time_frame>During the surgical sample collection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions</measure>
    <time_frame>During the surgical sample collection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A prospective 5-year follow-up of pain recurrence after surgical treatment of endometriosis</measure>
    <time_frame>5 years (annually) after the completion of patient recruitment</time_frame>
    <description>Questionnaire based evaluation of postoperative pain symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HE-4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women</measure>
    <time_frame>During surgical sample collection</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Endometriosis</arm_group_label>
    <description>Women (19-48 years of age) with surgically confirmed endometriosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy women</arm_group_label>
    <description>Healthy women (32-48 years of age), symptom free, existence of endometriosis ruled out during laparoscopy for tubal ligation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopy/laparotomy</intervention_name>
    <description>Surgical treatment of endometriosis (laparotomy/laparoscopy) or laparoscopic sterilisation. Sample collection in both groups.</description>
    <arm_group_label>Endometriosis</arm_group_label>
    <arm_group_label>Healthy women</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, peritoneal fluid, endometrium tissue, healthy peritoneum, tissue of endometriosis&#xD;
      (peritoneal, ovarian, deep infiltrating.&#xD;
&#xD;
      Extracted DNA, RNA, cDNA and protein from the above samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Endometriosis: Finnish Caucasian women surgically treated for endometriosis; age 19-48, no&#xD;
        significant other disease or medication for other diseases&#xD;
&#xD;
        Healthy controls: symptomless Finnish Caucasian women going through laparoscopy for tubal&#xD;
        ligation; age 32-48, no significant other disease or medication&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  study group: surgically and pathologically verified endometriosis&#xD;
&#xD;
          -  control group: existence of endometriosis ruled out in laparoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no other significant disease or medication for other diseases&#xD;
&#xD;
          -  suspicion of malignancy&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  acute infection&#xD;
&#xD;
          -  insufficient understanding of Finnish language&#xD;
&#xD;
          -  previous hysterectomy and/or bilateral salpingo-oophorectomy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antti Perheentupa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, Turku University Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antti H Perheentupa, MD PhD</last_name>
    <phone>+358-2-3130000</phone>
    <phone_ext>30222</phone_ext>
    <email>antti.perheentupa@utu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kaisa Huhtinen, PhD</last_name>
    <phone>+358-2-333 7376</phone>
    <email>kaisa.huhtinen@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of Obstetrics and Gynecology, Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dept of Obstetrics and Gynecology, North Carelia Central Hospital</name>
      <address>
        <city>Joensuu</city>
        <zip>80210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dept of Obstetrics and Gynecology, Päijät-Häme Central Hospital</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dept of Obstetrics and Gynecology, Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Perheentupa, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Kaisa Huhtinen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pia Suvitie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Gabriel M, Fey V, Heinosalo T, Adhikari P, Rytkönen K, Komulainen T, Huhtinen K, Laajala TD, Siitari H, Virkki A, Suvitie P, Kujari H, Aittokallio T, Perheentupa A, Poutanen M. A relational database to identify differentially expressed genes in the endometrium and endometriosis lesions. Sci Data. 2020 Aug 28;7(1):284. doi: 10.1038/s41597-020-00623-x.</citation>
    <PMID>32859947</PMID>
  </reference>
  <reference>
    <citation>Heinosalo T, Gabriel M, Kallio L, Adhikari P, Huhtinen K, Laajala TD, Kaikkonen E, Mehmood A, Suvitie P, Kujari H, Aittokallio T, Perheentupa A, Poutanen M. Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis. Hum Reprod. 2018 May 1;33(5):817-831. doi: 10.1093/humrep/dey026.</citation>
    <PMID>29462326</PMID>
  </reference>
  <results_reference>
    <citation>Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setälä M, Härkki P, Jalkanen J, Fraser J, Mäkinen J, Auranen A, Poutanen M, Perheentupa A. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009 Apr 21;100(8):1315-9. doi: 10.1038/sj.bjc.6605011. Epub 2009 Mar 31.</citation>
    <PMID>19337252</PMID>
  </results_reference>
  <results_reference>
    <citation>Hiissa J, Elo LL, Huhtinen K, Perheentupa A, Poutanen M, Aittokallio T. Resampling reveals sample-level differential expression in clinical genome-wide studies. OMICS. 2009 Oct;13(5):381-96. doi: 10.1089/omi.2009.0027.</citation>
    <PMID>19663710</PMID>
  </results_reference>
  <results_reference>
    <citation>Hallamaa M, Suvitie P, Huhtinen K, Matomäki J, Poutanen M, Perheentupa A. Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women. Gynecol Oncol. 2012 Jun;125(3):667-72. doi: 10.1016/j.ygyno.2012.03.011. Epub 2012 Mar 14.</citation>
    <PMID>22426487</PMID>
  </results_reference>
  <results_reference>
    <citation>Huhtinen K, Desai R, Ståhle M, Salminen A, Handelsman DJ, Perheentupa A, Poutanen M. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. J Clin Endocrinol Metab. 2012 Nov;97(11):4228-35. doi: 10.1210/jc.2012-1154. Epub 2012 Sep 11.</citation>
    <PMID>22969138</PMID>
  </results_reference>
  <results_reference>
    <citation>Huhtinen K, Saloniemi-Heinonen T, Keski-Rahkonen P, Desai R, Laajala D, Ståhle M, Häkkinen MR, Awosanya M, Suvitie P, Kujari H, Aittokallio T, Handelsman DJ, Auriola S, Perheentupa A, Poutanen M. Intra-tissue steroid profiling indicates differential progesterone and testosterone metabolism in the endometrium and endometriosis lesions. J Clin Endocrinol Metab. 2014 Nov;99(11):E2188-97. doi: 10.1210/jc.2014-1913. Epub 2014 Aug 19.</citation>
    <PMID>25137424</PMID>
  </results_reference>
  <results_reference>
    <citation>Vehmas AP, Muth-Pawlak D, Huhtinen K, Saloniemi-Heinonen T, Jaakkola K, Laajala TD, Kaprio H, Suvitie PA, Aittokallio T, Siitari H, Perheentupa A, Poutanen M, Corthals GL. Ovarian endometriosis signatures established through discovery and directed mass spectrometry analysis. J Proteome Res. 2014 Nov 7;13(11):4983-94. doi: 10.1021/pr500384n. Epub 2014 Aug 20.</citation>
    <PMID>25099244</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2011</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Antti Perheentupa</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>dysmenorrhea</keyword>
  <keyword>infertility</keyword>
  <keyword>biomarker</keyword>
  <keyword>drug target</keyword>
  <keyword>recurrence</keyword>
  <keyword>complications</keyword>
  <keyword>dyspareunia</keyword>
  <keyword>dyschezia</keyword>
  <keyword>dysuria</keyword>
  <keyword>chronic pelvic pain</keyword>
  <keyword>surgical treatment</keyword>
  <keyword>long-term follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

